Comparing end-of-life care of hematologic malignancy versus solid tumor patients in a tertiary care center

Article indépendant

BURSTEIN, Rachel | AVIV, Ariel | EVEN-ZOHAR, Noa Gross | NACHMIAS, Boaz | HARAN, Arnon | BRAUN, Michal | ROTTENBERG, Yakir | SHAULOV, Adir

Objectives: To compare end-of-life (EOL) care for solid tumor and hematologic malignancy (HM) patients. Methods: We collected data on the last 100 consecutive deceased HM and 100 consecutive deceased solid tumor patients who died prior to June 1st 2020, treated at a single center. We compared demographic parameters, cause of death as ascertained by review of medical records by two independent investigators, and EOL quality indicators including: place of death, use of chemotherapy or targeted/biologic treatment, emergency department visits as well as hospital, inpatient hospice and Intensive Care Unit admissions and the time spent as inpatient over the last 30 days of life; mechanical ventilation and use of blood products during the last 14 days of life. Results: In comparison with solid tumor patients, HM patients more commonly died from treatment complications (13% vs. 1%) and unrelated causes (16% vs. 2%, p < .001 for all comparisons). HM patients died more frequently than solid tumor patients in the intensive care unit (14% vs. 7%) and the emergency department (9% vs. 0%) and less frequently in hospice (9% vs. 15%, p = .005 for all comparisons). In the 2 weeks prior to death HM patients were more likely than solid tumor patients to undergo mechanical ventilation (14% vs. 4%, p = .013), receive blood (47% vs. 27%, p = .003) and platelet transfusions (32% vs. 7%, p < .001); however, no statistical difference was found in use of either of chemotherapy (18% vs. 13%, p = .28) or targeted treatment (10% vs. 5%, p = .16). Conclusions: HM patients were more likely than solid tumor patients to undergo aggressive measures at EOL. Rarity of HM deaths, frequently caused by complications of treatment and unrelated causes, may affect treatment choices at EOL.

http://dx.doi.org/10.1111/ejh.14035

Voir la revue «European journal of haematology»

Autres numéros de la revue «European journal of haematology»

Consulter en ligne

Suggestions

Du même auteur

Comparing end-of-life care of hematologic mal...

Article indépendant | BURSTEIN, Rachel | European journal of haematology

Objectives: To compare end-of-life (EOL) care for solid tumor and hematologic malignancy (HM) patients. Methods: We collected data on the last 100 consecutive deceased HM and 100 consecutive deceased solid tumor patients who died ...

Predictors of death at home among cancer pati...

Article indépendant | ROTTENBERG, Yakir | International journal for equity in health | n°1 | vol.20

Background: Most cancer patients prefer to die at home; however, many die in hospital. The aim of the current study is to elucidate the association between dying at home and various personal factors in the Israeli population of ca...

Predictors of death at home among cancer pati...

Article indépendant | ROTTENBERG, Yakir | International journal for equity in health | n°1 | vol.20

Background: Most cancer patients prefer to die at home; however, many die in hospital. The aim of the current study is to elucidate the association between dying at home and various personal factors in the Israeli population of ca...

De la même série

Palliative care utilization, transfusion burd...

Article indépendant | MCINTURF, Geoffrey | European journal of haematology

Introduction:Despite treatment advances, multiple myeloma (MM) remains a significant source of morbidity and mortality. We aimed to examine specialist palliative care (SPC) involvement and end-of-life care for patients with MM. Me...

Comparing end-of-life care of hematologic mal...

Article indépendant | BURSTEIN, Rachel | European journal of haematology

Objectives: To compare end-of-life (EOL) care for solid tumor and hematologic malignancy (HM) patients. Methods: We collected data on the last 100 consecutive deceased HM and 100 consecutive deceased solid tumor patients who died ...

Treatment sequences and drug costs from diagn...

Article indépendant | SEEFAT, M. R. | European journal of haematology

Novel therapies for multiple myeloma (MM) have improved patient survival, but their high costs strain healthcare budgets. End-of-life phases of treatment are generally the most expensive, however, these high costs may be less just...

Chargement des enrichissements...